453
Views
7
CrossRef citations to date
0
Altmetric
Review Article

Conservative Surgical Management of Placenta Accreta Spectrum: A Pragmatic Approach

ORCID Icon, , &

REFERENCES

  • Luke RK, Sharpe JW, Greene RR. Placenta accreta: the adherent or invasive placenta. Am J Obstet Gynecol. 1966;95(5):660–668.
  • Jauniaux E, Chantraine F, Silver RM; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: epidemiology. Int J Gynecol Obstet. 2018;140(3):265–273. doi:10.1002/ijgo.12407.
  • Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018;218(1):75–87.
  • Solheim KN, Esakoff TF, Little SE, et al. The effect of cesarean delivery rates on the future incidence of placenta previa, placenta accreta, and maternal mortality. J Matern Fetal Neonatal Med. 2011;24(11):1341–1346. doi:10.3109/14767058.2011.553695.
  • Cahill AG, Beigi R, Heine RP; Society of Gynecologic Oncology, American College of Obstetricians and Gynecologists and the Society for Maternal–Fetal Medicine, et al. Placenta accreta spectrum. Am J Obstet Gynecol. 2018;219(6):B2–B16.
  • Belfort MA, Shamshirsaz AA, Fox KA. The diagnosis and management of morbidly adherent placenta. Semin Perinatol. 2018;42(1):49–58. doi:10.1053/j.semperi.2017.11.009.
  • Cal M, Ayres-de-Campos D, Jauniaux E. International survey of practices used in the diagnosis and management of placenta accreta spectrum disorders. Int J Gynecol Obstet. 2018;140(3):307–311. doi:10.1002/ijgo.12391.
  • Sentilhes L, Ambroselli C, Kayem G, et al. Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol. 2010;115(3):526–534.
  • Matsuzaki S, Yoshino K, Endo M, et al. Conservative management of placenta percreta. Int J Gynecol Obstet. 2018;140(3):299–306. doi:10.1002/ijgo.12411.
  • Fox KA, Shamshirsaz AA, Carusi D, et al. Conservative management of morbidly adherent placenta: expert review. Am J Obstet Gynecol. 2015;213(6):755–760.
  • Pather S, Strockyj S, Richards A, et al. Maternal outcome after conservative management of placenta percreta at caesarean section: a report of three cases and a review of the literature. Aust N Z J Obstet Gynaecol. 2014;54(1):84–87. doi:10.1111/ajo.12149.
  • Clausen C, Lönn L, Langhoff-Roos J. Management of placenta percreta: a review of published cases. Acta Obstet Gynecol Scand. 2014;93:138–143. (2)doi:10.1111/aogs.12295.
  • Welsh AW, Ellwood D, Carter J, et al. Opinion: integration of diagnostic and management perspectives for placenta accreta. Aust N Z J Obstet Gynaecol. 2009;49(6):578–587.
  • Washecka R, Behling A. Urologic complications of placenta percreta invading the urinary bladder: a case report and review of the literature. Hawaii Med J. 2002;61(4):66–69.
  • Meyer NP, Ward GH, Chandraharan E. Conservative approach to the management of morbidly adherent placentae. Ceylon Med J. 2012;57(1):36–39. doi:10.4038/cmj.v57i1.4199.
  • Sentilhes L, Kayem G, Chandraharan E; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: conservative management. Int J Gynecol Obstet. 2018;140(3):291–298. doi:10.1002/ijgo.12410.
  • Kutuk MS, Ak M, Ozgun MT. Leaving the placenta in situ versus conservative and radical surgery in the treatment of placenta accreta spectrum disorders. Int J Gynecol Obstet. 2018;140(3):338–344. doi:10.1002/ijgo.12308.
  • Shamshirsaz AA, Fox KA, Erfani H, et al. Multidisciplinary team learning in the management of the morbidly adherent placenta: outcome improvements over time. Am J Obstet Gynecol. 2017;216(6):612.e1–612.e5. doi:10.1016/j.ajog.2017.02.016.
  • Shih JC, Palacios Jaraquemada JMP, Su YN, et al. Role of three-dimensional power Doppler in the antenatal diagnosis of placenta accreta: comparison with gray-scale and color Doppler techniques. Ultrasound Obstet Gynecol. 2009;33(2):193–203.
  • D’Antonio F, Iacovella C, Bhide A. Prenatal identification of invasive placentation using ultrasound: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2013;42(5):509–517. doi:10.1002/uog.13194.
  • Fitzpatrick KE, Sellers S, Spark P, et al. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG: Int J Obstet Gynecol. 2014;121(1):62–70 (discussion 70–71). doi:10.1111/1471-0528.12405.
  • Thurn L, Lindqvist PG, Jakobsson M, et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG: Int J Obstet Gynecol. 2016;123(8):1348–1355. doi:10.1111/1471-0528.13547.
  • Bowman ZS, Eller AG, Kennedy AM, et al. Accuracy of ultrasound for the prediction of placenta accreta. Am J Obstet Gynecol. 2014;211(2):177.e1–7.
  • Jauniaux E, Collins SL, Jurkovic D, et al. Accreta placentation: a systematic review of prenatal ultrasound imaging and grading of villous invasiveness. Am J Obstet Gynecol. 2016;215(6):712–721.
  • Collins SL, Ashcroft A, Braun T, et al. Proposal for standardized ultrasound descriptors of abnormally invasive placenta (AIP). Ultrasound Obstet Gynecol. 2016;47(3):271–275. doi:10.1002/uog.14952.
  • Alfirevic Z, Tang A-W, Collins SL; Ad-Hoc International AIP Expert Group, et al. Pro forma for ultrasound reporting in suspected abnormally invasive placenta (AIP): an international consensus. Ultrasound Obstet Gynecol. 2016;47:276–278. (3)doi:10.1002/uog.15810.
  • Buca D, Liberati M, Calì G, et al. Influence of prenatal diagnosis of abnormally invasive placenta on maternal outcome: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018;52:304–309. (3)doi:10.1002/uog.19070.
  • Jauniaux E, Alfirevic Z, Bhide AG, et al. Placenta praevia and placenta accreta: diagnosis and management: green-top guideline no. 27A. BJOG: Int J Obstet Gynecol. 2019;126(1):e1–e48. doi:10.1111/1471-0528.15306.
  • Jauniaux E, Bhide A, Kennedy A, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: prenatal diagnosis and screening. Int J Gynecol Obstet. 2018;140(3):274–280. doi:10.1002/ijgo.12408.
  • Obstetric care consensus no. 7: placenta accreta spectrum. Obstet Gynecol. 2018;132(6):e259–e275.
  • Robinson BK, Grobman WA. Effectiveness of timing strategies for delivery of individuals with placenta previa and accreta. Obstet Gynecol. 2010;116(4):835–842.
  • Allen L, Jauniaux E, Hobson S, et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: nonconservative surgical management. Int J Gynecol Obstet. 2018;140(3):281–290. doi:10.1002/ijgo.12409.
  • Collins SL, Alemdar B, van Beekhuizen HJ, et al. Evidence-based guidelines for the management of abnormally-invasive placenta (AIP): recommendations from the International Society for AIP. Am J Obstet Gynecol. 2019;220:511–526.
  • Balayla J, Bondarenko HD. Placenta accreta and the risk of adverse maternal and neonatal outcomes. J Perinat Med. 2013;41(2):141–149.
  • Jauniaux E, Dimitrova I, Kenyon N, et al. Impact of placenta previa with placenta accreta spectrum disorder on fetal growth. Ultrasound Obstet Gynecol. 2019. doi:10.1002/uog.20244
  • Warrick CM, Rollins MD. Peripartum anesthesia considerations for placenta accreta. Clin Obstet Gynecol. 2018;61(4):808–827.
  • Taylor NJ, Russell R. Anaesthesia for abnormally invasive placenta: a single-institution case series. Int J Obstet Anesth. 2017;30:10–15. doi:10.1016/j.ijoa.2017.01.008.
  • Lilker SJ, Meyer RA, Downey KN, et al. Anesthetic considerations for placenta accreta. Int J Obstet Anesth. 2011;20(4):288–292. doi:10.1016/j.ijoa.2011.06.001.
  • Oyelese Y, Smulian JC. Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol. 2006;107(4):927–941.
  • Butwick AJ, Carvalho B, El-Sayed YY. Risk factors for obstetric morbidity in patients with uterine atony undergoing caesarean delivery. Br J Anaesth. 2014;113(4):661–668.
  • Matsubara S, Kuwata T, Usui R, et al. Important surgical measures and techniques at cesarean hysterectomy for placenta previa accreta. Acta Obstet Gynecol Scand. 2013;92(4):372–377. doi:10.1111/aogs.12074.
  • Tam Tam KB, Dozier J, Martin JN. Approaches to reduce urinary tract injury during management of placenta accreta, increta, and percreta: a systematic review. J Matern-Fetal Neonat Med. 2012;25:329–334. (4)doi:10.3109/14767058.2011.576720.
  • Norris BL, Everaerts W, Posma E, et al. The urologist's role in multidisciplinary management of placenta percreta. BJU Int. 2016;117(6):961–965.
  • Belfort MA, Shamshiraz AA, Fox K. Minimizing blood loss at cesarean–hysterectomy for placenta previa percreta. Am J Obstet Gynecol. 2017;216(1):78.e1–78.e2. doi:10.1016/j.ajog.2016.10.030.
  • Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: use of prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2018;132(3):e103–e119.
  • Amsalem H, Kingdom JCP, Farine D, et al. Planned caesarean hysterectomy versus “conserving” caesarean section in patients with placenta accreta. J Obstet Gynaecol Can. 2011;33(10):1005–1010. doi:10.1016/S1701-2163(16)35049-6.
  • Elagamy A, Abdelaziz A, Ellaithy M. The use of cell salvage in women undergoing cesarean hysterectomy for abnormal placentation. Int J Obstet Anesth. 2013;22(4):289–293. doi:10.1016/j.ijoa.2013.05.007.
  • Lew E, Tagore S. Implementation of an obstetric cell salvage service in a tertiary women’s hospital. Singapore Med J. 2015;56(8):445–449. doi:10.11622/smedj.2015121.
  • WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–2116. doi:10.1016/S0140-6736(17)30638-4.
  • Sentilhes L, Goffinet F, Kayem G. Management of placenta accreta. Acta Obstet Gynecol Scand. 2013;92:1125–1134. (10)
  • Petrov DA, Karlberg B, Singh K, et al. Perioperative internal iliac artery balloon occlusion, in the setting of placenta accreta and its variants: the role of the interventional radiologist. Curr Probl Diagn Radiol. 2018;47:445–451. (6)doi:10.1067/j.cpradiol.2017.10.010.
  • Baldwin HJ, Patterson JA, Nippita TA, et al. Maternal and neonatal outcomes following abnormally invasive placenta: a population-based record linkage study. Acta Obstet Gynecol Scand. 2017;96(11):1373–1381.
  • Matsueda S, Hidaka N, Kondo Y, et al. External iliac artery thrombosis after common iliac artery balloon occlusion during cesarean hysterectomy for placenta accreta in cervico-isthmic pregnancy. J Obstet Gynaecol Res. 2015;41(11):1826–1830. doi:10.1111/jog.12777.
  • Zhang N, Lou W-H, Zhang X-B, et al. Vascular complications following prophylactic balloon occlusion of the internal iliac arteries resolved by successful interventional thrombolysis in a patient with morbidly adherent placenta. J Zhejiang Univ Sci B. 2017;18(3):272–276. doi:10.1631/jzus.B1600315.
  • Kayem G, Keita H. [Management of placenta previa and accreta]. J Gynecol Obstet Biol Reprod (Paris). 2014;43(10):1142–1160.
  • Kutuk MS, Kilic A, Ak M, Ozgun M. Infectious complications in morbidly adherent placenta treated with leaving placenta in situ: a cohort series and suggested approach. J Matern Fetal Neonatal Med. 2019;32(21):3520–3525.
  • Lin K, Qin J, Xu K, et al. Methotrexate management for placenta accreta: a prospective study. Arch Gynecol Obstet. 2015;291(6):1259–1264.
  • Imai S, Kondoh E, Kawasaki K, et al. Placental blood flow disappears coincident with a fall in human chorionic gonadotropin to undetectable levels in conservative management of placenta accreta. Eur J Obstet Gynecol Reprod Biol. 2014;180:199–201. doi:10.1016/j.ejogrb.2014.05.020.
  • Soyer P, Sirol M, Fargeaudou Y, et al. Placental vascularity and resorption delay after conservative management of invasive placenta: MR imaging evaluation. Eur Radiol. 2013;23(1):262–271. doi:10.1007/s00330-012-2573-4.
  • Hequet D, Morel O, Soyer P, et al. Delayed hysteroscopic resection of retained tissues and uterine conservation after conservative treatment for placenta accreta. Aust NZ J Obstet Gynaecol. 2013;53(6):580–583. doi:10.1111/ajo.12138.
  • Legendre G, Zoulovits FJ, Kinn J, et al. Conservative management of placenta accreta: hysteroscopic resection of retained tissues. J Minim Invasive Gynecol. 2014;21(5):910–913. doi:10.1016/j.jmig.2014.04.004.
  • Sentilhes L, Kayem G, Ambroselli C, et al. Fertility and pregnancy outcomes following conservative treatment for placenta accreta. Hum Reprod. 2010;25(11):2803–2810. doi:10.1093/humrep/deq239.
  • Provansal M, Courbiere B, Agostini A, et al. Fertility and obstetric outcome after conservative management of placenta accreta. Int J Gynaecol Obstet. 2010;109(2):147–150. doi:10.1016/j.ijgo.2009.12.011.
  • Salomon LJ, deTayrac R, Castaigne-Meary V, et al. Fertility and pregnancy outcome following pelvic arterial embolization for severe post-partum haemorrhage: a cohort study. Hum Reprod. 2003;18(4):849–852. doi:10.1093/humrep/deg168.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.